ID   YES-1
AC   CVCL_E321
SY   YES1
DR   cancercelllines; CVCL_E321
DR   GEO; GSM301574
DR   Progenetix; CVCL_E321
DR   Wikidata; Q54995399
RX   DOI=10.5833/jjgs.27.1885;
RX   PubMed=1770930;
RX   PubMed=1819237;
RX   PubMed=8590302;
RX   PubMed=8974001;
RX   PubMed=11115554;
RX   PubMed=18575732;
RX   PubMed=18973137;
RX   PubMed=20515944;
CC   Population: Japanese.
CC   Doubling time: 35.2 hours (PubMed=1770930); 82.1 hours (DOI=10.5833/jjgs.27.1885).
CC   HLA typing: A*02,01; B*15,11; C*03 (PubMed=18575732).
CC   Omics: Transcriptomics; Microarray.
CC   Omics: Variations; Array-based CGH.
CC   Derived from site: In situ; Esophagus; UBERON=UBERON_0001043.
DI   NCIt; C4024; Esophageal squamous cell carcinoma
DI   ORDO; Orphanet_99977; Squamous cell carcinoma of the esophagus
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   50Y
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 10-04-25; Version: 14
//
RX   DOI=10.5833/jjgs.27.1885;
RA   Kusanagi H.;
RT   "Effect of epidermal growth factor (EGF) on human esophageal cancer
RT   cell lines in a protein-free medium and the expression of EGF
RT   receptors on the cells.";
RL   Nihon Shokaki Geka Gakkai Zasshi 27:1885-1891(1994).
//
RX   PubMed=1770930;
RA   Murakami T., Nakamura M., Kusanagi H., Suzuki T.;
RT   "Establishment and characterization of human esophageal carcinoma cell
RT   lines -- especially the role of the serum-free culture.";
RL   Nihon Geka Gakkai Zasshi 92:1563-1570(1991).
//
RX   PubMed=1819237;
RA   Nakamura M.;
RT   "Establishment and characterization of a new human esophageal cancer
RT   cell line (YES-1).";
RL   Nihon Geka Hokan 60:3-12(1991).
//
RX   PubMed=8590302; DOI=10.1089/jir.1995.15.1005;
RA   Oka M., Hirose K., Iizuka N., Aoyagi K., Yamamoto K., Abe T.,
RA   Hazama S., Suzuki T.;
RT   "Cytokine mRNA expression patterns in human esophageal cancer cell
RT   lines.";
RL   J. Interferon Cytokine Res. 15:1005-1009(1995).
//
RX   PubMed=8974001; DOI=10.1089/jir.1996.16.1001;
RA   Oka M., Iizuka N., Yamamoto K., Gondo T., Abe T., Hazama S.,
RA   Akitomi Y., Koishihara Y., Ohsugi Y., Ooba Y., Ishihara T.,
RA   Suzuki T.;
RT   "The influence of interleukin-6 on the growth of human esophageal
RT   cancer cell lines.";
RL   J. Interferon Cytokine Res. 16:1001-1006(1996).
//
RX   PubMed=11115554; DOI=10.3892/ijo.18.1.157;
RA   Fujii T., Kato S., Yamana H., Tanaka Y., Fujita H., Shirouzu K.,
RA   Morimatsu M.;
RT   "Expression of G1 cell cycle markers and the effect of
RT   adenovirus-mediated overexpression of p21Waf-1 in squamous cell
RT   carcinoma of the esophagus.";
RL   Int. J. Oncol. 18:157-163(2001).
//
RX   PubMed=18575732; DOI=10.3892/or.20.1.155;
RA   Kawaoka T., Oka M., Takashima M., Ueno T., Yamamoto K., Yahara N.,
RA   Yoshino S., Hazama S.;
RT   "Adoptive immunotherapy for pancreatic cancer: cytotoxic T lymphocytes
RT   stimulated by the MUC1-expressing human pancreatic cancer cell line
RT   YPK-1.";
RL   Oncol. Rep. 20:155-163(2008).
//
RX   PubMed=18973137; DOI=10.1002/gcc.20626;
RA   Sugimoto T., Seki N., Shimizu S., Kikkawa N., Tsukada J., Shimada H.,
RA   Sasaki K., Hanazawa T., Okamoto Y., Hata A.;
RT   "The galanin signaling cascade is a candidate pathway regulating
RT   oncogenesis in human squamous cell carcinoma.";
RL   Genes Chromosomes Cancer 48:132-142(2009).
//
RX   PubMed=20515944; DOI=10.1158/1535-7163.MCT-09-0918; PMCID=PMC2884061;
RA   Seki N., Toh U., Sayers T.J., Fujii T., Miyagi M., Akagi Y.,
RA   Kusukawa J., Kage M., Shirouzu K., Yamana H.;
RT   "Bortezomib sensitizes human esophageal squamous cell carcinoma cells
RT   to TRAIL-mediated apoptosis via activation of both extrinsic and
RT   intrinsic apoptosis pathways.";
RL   Mol. Cancer Ther. 9:1842-1851(2010).
//